Pilar Delgado

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3175051/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	2.0	431
2	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	2.0	350
3	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	2.0	264
4	Meta-analysis of Genome-wide Association Studies Identifies 1q22 as a Susceptibility Locus for Intracerebral Hemorrhage. American Journal of Human Genetics, 2014, 94, 511-521.	6.2	235
5	Higher Risk of Further Vascular Events Among Transient Ischemic Attack Patients With Diffusion-Weighted Imaging Acute Ischemic Lesions. Stroke, 2004, 35, 2313-2319.	2.0	210
6	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	2.0	204
7	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	2.0	199
8	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	2.0	199
9	Microbleeds Versus Macrobleeds. Stroke, 2009, 40, 2382-2386.	2.0	169
10	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	2.0	146
11	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	2.0	128
12	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	2.0	119
13	Monitoring intracranial pressure in patients with malignant middle cerebral artery infarction: is it useful?. Journal of Neurosurgery, 2010, 112, 648-657.	1.6	103
14	Hyperglycemia during Ischemia Rapidly Accelerates Brain Damage in Stroke Patients Treated with tPA. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1616-1622.	4.3	101
15	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. Stroke, 2008, 39, 1456-1463.	2.0	89
16	Heritability Estimates Identify a Substantial Genetic Contribution to Risk and Outcome of Intracerebral Hemorrhage. Stroke, 2013, 44, 1578-1583.	2.0	88
17	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	2.0	83
18	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator, Stroke, 2007, 38, 1076-1078,	2.0	75

PILAR DELGADO

#	Article	IF	CITATIONS
19	MMPâ€2/MMPâ€9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathyâ€Associated Hemorrhagic Stroke. Brain Pathology, 2012, 22, 133-141.	4.1	73
20	Short-Term Blood Pressure Variability Relates to the Presence of Subclinical Brain Small Vessel Disease in Primary Hypertension. Hypertension, 2015, 66, 634-640.	2.7	72
21	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	2.4	68
22	Quality of life and neurobehavioral changes in survivors of malignant middle cerebral artery infarction. Journal of Neurology, 2009, 256, 1126-1133.	3.6	65
23	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE, 2011, 6, e16750.	2.5	60
24	Combination of Thrombolysis and Statins in Acute Stroke Is Safe. Stroke, 2016, 47, 2870-2873.	2.0	58
25	Transcranial Duplex Sonography for Monitoring Hyperacute Intracerebral Hemorrhage. Stroke, 2009, 40, 987-990.	2.0	55
26	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. Ultrasound in Medicine and Biology, 2008, 34, 1573-1577.	1.5	53
27	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	2.0	46
28	Determinants of White Matter Hyperintensity Volume inÂPatients with Acute Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2010, 19, 230-235.	1.6	42
29	Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. Neurodegenerative Diseases, 2012, 10, 320-323.	1.4	41
30	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. Cerebrovascular Diseases, 2012, 33, 55-63.	1.7	41
31	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. BMC Neurology, 2013, 13, 130.	1.8	41
32	Is it Time to Reassess the SITS-MOST Criteria for Thrombolysis?. Stroke, 2009, 40, 2568-2571.	2.0	40
33	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. Stroke, 2008, 39, 1730-1734.	2.0	39
34	Burden of Risk Alleles for Hypertension Increases Risk of Intracerebral Hemorrhage. Stroke, 2012, 43, 2877-2883.	2.0	39
35	A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Annals of Neurology, 2012, 72, 716-729	5.3	39
36	Lipoprotein-Associated Phospholipase A ₂ Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	1.7	36

PILAR DELGADO

#	Article	IF	CITATIONS
37	Neuronal TIMPâ€1 release accompanies astrocytic MMPâ€9 secretion and enhances astrocyte proliferation induced by βâ€amyloid 25–35 fragment. Journal of Neuroscience Research, 2009, 87, 2115-2125.	2.9	34
38	Genetic variants inCETPincrease risk of intracerebral hemorrhage. Annals of Neurology, 2016, 80, 730-740.	5.3	33
39	Prevalence of hippocampal enlarged perivascular spaces in a sample of patients with hypertension and their relation with vascular risk factors and cognitive function. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 651-656.	1.9	32
40	Prevalence and Associated Factors of Silent Brain Infarcts in a Mediterranean Cohort of Hypertensives. Hypertension, 2014, 64, 658-663.	2.7	30
41	<i>IL1B</i> and <i>VWF</i> Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke. Stroke, 2012, 43, 2659-2665.	2.0	28
42	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.8	24
43	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	2.1	23
44	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	1.7	23
45	GRECOS Project (Genotyping Recurrence Risk of Stroke). Stroke, 2017, 48, 1147-1153.	2.0	23
46	KCNK17 genetic variants in ischemic stroke. Atherosclerosis, 2010, 208, 203-209.	0.8	22
47	ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging, 2011, 32, 551.e13-551.e22.	3.1	22
48	Obstructive sleep apnea and silent cerebral infarction in hypertensive individuals. Journal of Sleep Research, 2018, 27, 232-239.	3.2	22
49	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	3.4	19
50	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	1.3	18
51	N-terminal pro-brain natriuretic peptide and subclinical brain small vessel disease. Neurology, 2016, 87, 2533-2539.	1.1	18
52	Microalbuminuria and the Combination of MRI Markers of Cerebral Small Vessel Disease. Cerebrovascular Diseases, 2016, 42, 66-72.	1.7	17
53	Blood Biomarkers in Cardioembolic Stroke. Current Cardiology Reviews, 2010, 6, 194-201.	1.5	16
54	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis, 2012, 220, 532-536.	0.8	14

PILAR DELGADO

#	Article	IF	CITATIONS
55	High daytime and nighttime ambulatory pulse pressure predict poor cognitive function and mild cognitive impairment in hypertensive individuals. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 253-263.	4.3	14
56	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	2.0	13
57	Biological Age Acceleration Is Lower in Women With Ischemic Stroke Compared to Men. Stroke, 2022, 53, 2320-2330.	2.0	11
58	Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women. Atherosclerosis, 2014, 237, 811-815.	0.8	10
59	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. European Neurology, 2011, 65, 82-87.	1.4	8
60	Neuroprotection in Malignant MCA Infarction. Cerebrovascular Diseases, 2006, 21, 99-105.	1.7	7
61	Presurgical evaluation in refractory epilepsy secondary to meningitis or encephalitis: bilateral memory deficits often preclude surgery. Epileptic Disorders, 2007, 9, 127-133.	1.3	7
62	Exome Sequencing and Clot Lysis Experiments Demonstrate the R458C Mutation of the Alpha Chain of Fibrinogen to be Associated with Impaired Fibrinolysis in a Family with Thrombophilia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 431-440.	2.0	6
63	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke/subtitle. Thrombosis and Haemostasis, 2016, 116, 1165-1771.	3.4	6
64	Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards. Clinical Neuropsychologist, 2016, 30, 1443-1456.	2.3	5
65	Identification of Plasma Biomarkers of Human Intracerebral Hemorrhage Subtypes through Microarray Technology. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 665-671.	1.6	4
66	Nâ€glycome Profile Levels Relate to Silent Brain Infarcts in a Cohort of Hypertensives. Journal of the American Heart Association, 2015, 4, .	3.7	3
67	Blood biomarkers to identify ischemic stroke etiologies. Therapy: Open Access in Clinical Medicine, 2010, 7, 337-353.	0.2	1
68	Letter by Riba-Llena et al Regarding Article, "Not Listened or Not Reported Rather Than Silent Stroke― Stroke, 2013, 44, e42.	2.0	1
69	Response to Letter by Poppe et al. Stroke, 2008, 39, .	2.0	0
70	Control de la presión arterial tras el ictus, ¿nos pasamos o no llegamos?. Hipertension Y Riesgo Vascular, 2011, 28, 1-3.	0.6	0